Mirum Pharmaceuticals said it mapped out an FDA path after volixibat produced a Phase 2 win by significantly reducing severe itching in patients with a rare liver disease. The report characterizes the result as strong enough to support planning toward regulatory filing. Volixibat is positioned in a specialty niche where symptom burden is central to clinical endpoints and regulatory conversations often hinge on magnitude, durability, and safety. Progression from Phase 2 into an FDA submission workflow is a high-signal milestone for small molecules in this category. The update also implies increased attention on endpoint selection and statistical strategy for the FDA review package, especially for trials focused on pruritus severity. Investors typically treat the “FDA filing pathway” signal as more than marketing, because it usually reflects internal readiness on manufacturing, toxicology, and clinical data completeness.